Economic Evaluation of NT-proBNP Supported Guideline-Directed Medical Therapy in Discharged Patients with Heart Failure in China



LI Liwen¹, CHEN Ailan², XIA Shuang¹, ZHANG Yue³, XUAN Jianwei⁴,

¹ Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China ² Department of Cardiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

³ Roche Diagnostics (Shanghai) Limited, Shanghai, China

⁴ Health Economic Research Institute, School of Pharmacy, Sun Yat-sen University, Guangzhou, China

BACKGROUND

- Heart failure (HF) is a significant public health challenge in China, with a prevalence of 15 million patients, accounting for about 1/4 of the global total^[1].
- Acute HF is particularly prevalent and costly, leading to high rates of readmission (32.4%)^[2] and mortality (13.7%)^[3] within one year post-discharge.
- Chinese HF patients have limited follow-up and suboptimal use of guidelinedirected medical therapy (GDMT) after discharge^[4].
- The STRONG-HF trial demonstrated that intensified follow-up visits with pro-B-type natriuretic N-terminal monitored peptide (NT-proBNP) concentrations, guiding rapid up-titration of medications, reduced all cause

Key Assumptions

- The study population, usual care provided to patients, local implementation of high-intensity care, and treatment effects observed in the STRONG-HF study are relevant to China.
- The cost of hospitalization due to the initial acute HF event was not considered, as these costs would be identical for both groups.
- Patients were assumed to receive either 0%, 50%, 75%, or 100% of the full optimal doses, in alignment with the dose level categorization used in the STRONG-HF study.
- Other laboratory testing included blood routine, urine routine, electrolytes, liver function, kidney function, and estimated glomerular filtration rate (eGFR) testing.

death or HF readmission by 34% within 180 days^[5].

Chinese clinical guidelines have recommended intensified follow-up visits and high-intensity care for HF patients after discharge based on the STRONG-HF study^[6]. However, the economic impact of NT-proBNP-supported GDMT remains unknown, necessitating further evaluation.

OBJECTIVE

To evaluate the extent to which the higher costs associated with up-titration of HF GDMT can be offset by the avoidance of HF readmissions within 180 days after discharge.

METHODS

- This study builds upon the STRONG-HF study and employs a research methodology grounded in the Expert Consensus on Pharmacoeconomic Evaluations Alongside Clinical Trials (2024 edition) to construct the analysis^[7].
- A cost analysis was performed using a within-trial analysis and a decision-tree \bullet model to compare total medical costs of high-intensity care versus usual care in HF patients after discharge within 180 days(Figure.1).
- High-intensity care included five follow-up visits at 1, 2, 3, and 6 weeks, and ulletagain at 90 after discharge. These visits closely monitored clinical status, lab testing, and NT-proBNP levels. Usual care included follow-up visits only at 90 days post-discharge.

RESULTS

- Compared with usual care, high-intensity care of GDMT reduced all-cause death or HF readmission by 34.8% from 23.3% to 15.2% after discharge within 180 days.
- High-intensity care decreased total medical cost per capita by 9.7% (599.8 CNY) from 6,187.6 CNY to 5,587.8 CNY as well. Despite the increased costs associated with lab testing (1,445.3CNY) and medication (152.7CNY) for highintensity care, these were offset by the decreased readmission cost of 2,260.7 CNY (Table 2).


Table.2 Base case results

Cost Category	Usual care	High-intensity care	Difference
Lab testing cost* (¥)	362.9	1,808.3	+1,445.3
Drug cost (¥)	722.3	875.0	+152.7
Readmission cost(¥)	5,086.6	2,825.9	-2260.7
Total medical cost(¥)	6,187.6	5,587.8	-599.8


*include NT-proBNP and other lab testing cost

Sensitivity analyses

- Clinical event rates and health resource utilization data, as well as treatment \bullet effects, aligned with the STRONG-HF study.
- Cost inputs, including NT-proBNP and other laboratory testing costs, physician \bullet visit costs, drug costs, and HF readmission costs, were derived from published literature or local public databases in China (Table 1).
- Robustness of the results were assessed through deterministic sensitivity analyses (DSA).



One-way sensitivity analysis via changing every inputs by ranging from 20% to 10% showed that the HF readmission rate of usual care had the greatest impact on the results followed by HF hospitalization cost.



CONCLUSIONS

NT-proBNP supported GDMT not only improves health outcomes but offers significant cost savings, demonstrating dominant economic advantage in acute

Figure.1 Decision tree

Table.1 Cost inputs

Cost Category		Unit cost (CNY)
NT-proBNP testing cost		¥150.0
Other lab testing cost		¥219.5
Physician visit cost		¥16.0
Average daily drug cost	MRA	¥1.2
	ARNi	¥9.5
	SGLT-2 inhibitors	¥3.8
Average cost per HF hospitalization		¥29,745.9

CONTACT INFORMATION: yue.zhang.yz13@roche.com

HF patients after discharge in China.

REFERENCES

[1] Institute of Health Metrics and Evaluation. (2023, May 27). Global Burden of Disease (GBD) study. https://vizhub.healthdata.org/gbd-results/. [2] The Writing Committee of the Report on Cardiovascular Health and Diseases in China. (2021). Report on cardiovascular health and diseases burden in China: An updated summary of 2020. Chinese Circulation Journal, 36(6), 521-545. DOI:10.3969/j.issn.1000-3614.2021.06.001. [3] Wang, H., Li, Y., Chai, K., Long, Z., Yang, Z., Du, M., Wang, S., Zhan, S., Liu, Y., Wan, Y., Wang, F., Yin, P., Li, W., Liao, Y., Dong, Y., Li, X., Zhou, J., Yiu, K. H., Zhou, M., Huo, Y., & Yang, J. (2024). Mortality in patients admitted to hospital with heart failure in China: A nationwide Cardiovascular Association Database-Heart Failure Centre Registry cohort study. Lancet Global Health, 12(4), e611-e622. doi: 10.1016/S2214-109X(23)00605-8. PMID: 38485428.

[4] Wang, W., Lei, L., Zhao, Q., et al. (2023). Progress in the study of prediction models for readmission and death risk in patients with acute heart failure. Chinese Journal of Epidemiology, 44(12), 2005-2011. DOI:10.3760/cma.j.cn112338-20230527-00336.

[5] Mebazaa, A., Davison, B., Chioncel, O., Cohen-Solal, A., Diaz, R., Filippatos, G., Metra, M., Ponikowski, P., Sliwa, K., Voors, A. A., Edwards, C., Novosadova, M., Takagi, K., Damasceno, A., Saidu, H., Gayat, E., Pang, P. S., Celutkiene, J., & Cotter, G. (2022). Safety, tolerability and efficacy of uptitration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial. Lancet, 400(10367), 1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7. PMID: 36356631.

[6] National Center for Cardiovascular Diseases, National Expert Committee on Heart Failure, Chinese Medical Doctor Association Heart Failure Professional Committee, et al. (2023). National Heart Failure Guidelines 2023. Chinese Journal of Heart Failure and Cardiomyopathy, 07(04), 215-311. DOI:10.3760/cma.j.issn.101460-20231209-00052.

[7] Chinese Pharmaceutical Association Pharmaceutical Economics Professional Committee. (2024). Expert consensus on clinical trial embedding pharmacoeconomic evaluation (2024 edition). Chinese Medical Journal, 104(40), 3736-3744. DOI: 10.3760/cma.j.cn112137-20240422-00954.